Myeloid growth factors after induction of AML – pro
Treating with Neulasta after induction of acute myelogenous leukemia i controversial, becauseu it can thoretically reinduce AML cells. ASCO has not position on it in adults but recommends against it in children. AHRGQ does ot recommend it. I sys: “Induction chemotherapy adjuvants such as granulocyte-colony stimulating factor (GCSF) or granulocyte-macrophage (GM)-CSF, interleukin-11, or multidrug resistance modulators such as cyclosporine A, PSC-833 (valspodar), and zosuquidar are not recommended.” NCCN does not list it.
AHRQ GUIDELINE SUMMARY NGC:010926 2016 FEB 2 Systemic treatment of acute myeloid leukemia (AML).
Thomas J. Smith, Kari Bohlke, Gary H. Lyman, Kenneth R. Carson, Jeffrey Crawford, Scott J. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Clinical Oncology 33, no. 28 (October 2015) 3199-3212.
NCCN AML 2017